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Introduction
Herpes simplex encephalitis (HSE) is the most common
sporadic viral encephalitis in children in Western coun-
tries. Only early administration of antiviral drugs can
improve the mortality rate, which goes up to 70% without
treatment. In different pediatric studies on children with
HSE treated by acyclovir about 50% of patients recovered
fully, whereas about 40% stayed with moderate to severe
neurological impairment. Recent studies reported that
specific genetic immunodeficiencies lead to increased
HSE susceptibility and that secondary immune-mediated
processes can modify disease evolution. Some of these
immunodeficiencies such as defects in Toll-like receptor
signalling can be detected by cheap and fast tests.
Case report
A 2 years old boy with uneventful medical history and
psychomotor development presented with prolonged
clonic seizures, followed by gradually loss of conscious-
ness. Immediately acyclovir treatment was started in spite
of negative HSV PCR in cerebrospinal fluid (CSF) analysis.
While the boy further clinically deteriorated and cMRI
revealed diffuse hyperintensity in the right hemisphere, a
repeat analysis of HSV PCR in CSF was initiated and gave
a positive result. Antiviral treatment was continued for a
total of 24 days. The boy was discharged on day 25 with
still severe impaired consciousness and neurological
sequelae. He was readmitted on day 30 with newly
occurred dysphagia. HSV PCR in CSF was negative and
cMRI showed no significant disease progression. An
immunomodulatory treatment with corticosteroids
(methylprednisolone) was given in combination with
acyclovir for another 14 days to prevent an early relapse.
Standard blood tests and medical history revealed no
immunodeficiency. However, specific stimulation of the
boy's peripheral blood monocytes showed impaired anti-
viral interferon-production indicating a specific immuno-
deficiency, which predisposes him for severe HSE.
Therefore, prophylactic treatment with acyclovir orally
was started. Molecular studies to identify a possible
genetic defect in the Toll-like receptor pathway are ongo-
ing.
Conclusion
We report on a boy with increased immunological suscep-
tibility to life-threatening HSV infections. In the diagnos-
tic and therapeutic work-up of patients with secondary
disease progression one should consider HSE relapse as
well as postinfectious immune-mediated processes.
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